Compare BANR & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANR | TRVI |
|---|---|---|
| Founded | 1890 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 2015 | 2019 |
| Metric | BANR | TRVI |
|---|---|---|
| Price | $70.29 | $17.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $70.00 | $21.55 |
| AVG Volume (30 Days) | 424.7K | ★ 3.0M |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | 15.57 | ★ 31.91 |
| EPS | ★ 1.60 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.73 | N/A |
| Revenue Next Year | $5.69 | N/A |
| P/E Ratio | $43.03 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $57.05 | $6.55 |
| 52 Week High | $72.65 | $20.22 |
| Indicator | BANR | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 57.62 | 50.62 |
| Support Level | $62.97 | $10.07 |
| Resistance Level | $72.65 | $20.19 |
| Average True Range (ATR) | 1.57 | 1.40 |
| MACD | -0.00 | -0.23 |
| Stochastic Oscillator | 60.71 | 27.89 |
Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho, and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.